ArticleScientific reports2026
Seroprevalence and determinants of hepatitis E virus infection among people living with HIV in Chiang Mai, Thailand: a cross-sectional analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatitis E in Thailand: From Seroprevalence to Foodborne and Transfusion-Associated Risks.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatitis E virus (HEV) is increasingly recognized as a cause of acute viral hepatitis, with particular concern in immunocompromised populations, including people living with HIV (PLHIV). Despite global interest, data on HEV epidemiology among PLHIV in Thailand remain limited. This study aimed to estimate the seroprevalence of anti-HEV IgG antibodies among PLHIV in Chiang Mai, Thailand, and to identify demographic, behavioural, and clinical factors independently associated with HEV exposure. A cross-sectional study was conducted among 200 PLHIV attending four referral hospitals in Chiang Mai province. Plasma samples were tested for anti-HEV IgG using enzyme-linked immunosorbent assay (ELISA). Other hepatotropic viruses including hepatitis B and C were also assessed. Logistic regression was employed to assess predictors of HEV seropositivity. Anti-HEV IgG antibodies were detected in 13.0% (26/200) of participants. Seroprevalence did not significantly differ by sex (15.0% in males vs. 11.0% in females; p = 0.543). HBsAg and anti-HCV were observed in 6.5% and 8.0% of participants, respectively, with anti-HCV significantly more prevalent among males (15.0%) than females (1.0%; p < 0.001). Multivariate analysis identified three independent factors associated with HEV seropositivity: age ≥ 50 years (adjusted OR 3.40; 95% CI 1.47-7.86; p = 0.004), history of needle stick injury (adjusted OR 3.33; 95% CI 1.20-9.24; p = 0.021), and renal failure (adjusted OR 15.69; 95% CI 2.93-83.87; p = 0.001). HEV exposure among PLHIV in northern Thailand is not uncommon and is associated with older age, history of renal dysfunction, and potential parenteral exposures. These findings support targeted HEV screening and reinforce the need for broader HEV surveillance and preventive strategies within vulnerable HIV-positive populations in Southeast Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.